**Neurochemical correlates of autistic disorder: A review of the literature**

Kristen S.L. Lam, Neurodevelopmental Disorders Research Center, University of North Carolina at Chapel Hill, NC, USA, Michael G. Aman, The Nisonger Center, The Ohio State University, 1581 Dodd Drive, Columbus, OH 43210, USA, L. Eugene Arnold, The Nisonger Center, The Ohio State University, 1581 Dodd Drive, Columbus, OH 43210, USA

**Abstract**

Review of neurochemical investigations in autistic disorder revealed that a wide array of transmitter systems have been studied, including serotonin, dopamine, norepinephrine, acetylcholine, oxytocin, endogenous opioids, cortisol, glutamate, and gamma-aminobutyric acid (GABA). These studies have been complicated by the fact that autism is a very heterogeneous disorder which often presents with comorbid behavioral problems. In addition, many of these studies employed very small samples and inappropriate control groups, making it difficult to draw conclusions with confidence. Overall, serotonin appears to have the most empirical evidence for a role in autism, but this requires further investigation and replication. There is little support for the notion that a dysfunction of norepinephrine or the endogenous opioids are related to autism. The role of dopaminergic functioning has not been compelling thus far, though conflicting findings on central dopamine turnover require further study. Promising new areas of study may include possible dysfunction of the cholinergic system, oxytocin, and amino acid neurotransmitters. Implications for pharmacotherapy are briefly discussed for each neurotransmitter system with brief research examples. Review of this work emphasizes the need for future studies to control for subject variables, such as race, sex, pubertal status, and distress associated with blood draws, which can affect measures of neurochemical function. In addition, research in neurochemistry must continue to work in concert with other subspecialties to form a more comprehensive and theory-based approach to the neurobiological correlates of autistic disorder.

1. **Neurochemical correlates of autistic disorder**

Autism is a pervasive developmental disorder characterized by impaired social interaction, deficits in verbal and nonverbal communication, and stereotyped interests and behaviors. Although the estimated prevalence in the general population ranges from 0.04 to 0.2% (Sponheim & Skjeldal, 1998; Chakrabarti & Fombonne, 2001), its emergence early in life, its profound impact on families, and its chronic course have resulted in enormous emotional and financial costs (Bristol et al., 1996). It is now widely accepted that autism is a neurobiological disorder, though specific biological markers have yet to be found. However, there are aspects of the disorder which may guide future investigations into its pathophysiology. First, this is a developmental syndrome that is always observed before 3 years of age. Some families have even reported abnormalities in social interests within the first few months of life (Lord, 1995). Therefore, relevant neurochemical or neuroanatomical events may occur relatively early in the development of the central nervous system (CNS). Affected individuals also exhibit a range of cognitive deficits, with approximately 75% functioning within the range of mental retardation (Gillberg & Coleman, 1992). In addition, a substantial proportion (up to 50%) of patients with autism have abnormal EEGs (Trottier, Srivastava, & Walker, 1999), further suggesting underlying brain dysfunction. As is the case with
many neurodevelopmental syndromes, boys are affected about four times more often than girls (Gillberg & Coleman, 1992). There is now strong evidence that autism has a genetic component. Siblings of individuals with autism have a prevalence of 2.9 to 3.7%, which represents a nearly 100-fold increased risk relative to the general population (Bolton et al., 1994; Jorde et al., 1990; Szatmari & Jones, 1991). Twin studies have found concordance among monozygotic twins to range between 36 and 91%, whereas concordance in dizygotic twins was 1% (Bailey et al., 1995; Steffenberg et al., 1989). It is not clear why Bailey et al. and Steffenberg et al. found rates less than 1% for dizygotic twins whereas Bolton et al., Jorde et al., and Szatmari and Jones found rates of 2.9–3.7% among siblings. However, these findings all stress the importance of neurobiological investigation with regard to the development and expression of autistic disorder.

Although there is general agreement on the clinical features which define autism, aspects of the disorder’s presentation pose obstacles for scientific study. First, there is a tremendous range of syndrome expression across individuals according to age or developmental level (Volkmar, 2001). This heterogeneity of syndrome expression can create difficulties in accurately diagnosing autism, particularly among the youngest and lowest-functioning individuals (Lord, 1995; Volkmar & Lord, 1998). In particular, some children may exhibit the characteristic impaired social interest in the first few years of life but may not exhibit the unusual stereotyped behaviors and resistance to change until the following year or two (Lord, 1995). These same issues of symptom emergence are also found when attempting to diagnose profoundly retarded individuals, whose limited functional level makes detection of some of the features of autism difficult.

Another obstacle to the study of autism involves the comorbidity of individuals with autism (Volkmar & Lord, 1998). Often, people with autism not only present with the classic features of the disorder, but also with associated behavioral problems such as hyperactivity, attentional difficulties, perseveration, self-injury, and aggression. Currently, there is a tension between the two official diagnostic systems; the Diagnostic and Statistical Manual of Mental Disorders (4th ed. [DSM-IV]; American Psychiatric Association, 1994), which tends to focus on symptoms, as opposed to the International Classification of Diseases-10th edition (World Health Organization, 1994), which tends to focus on the single, all-encompassing syndrome (Angold, Costello, & Erkanli, 1999). These issues become particularly relevant when working with higher-functioning individuals with autism, in whom features of many different psychiatric conditions may be exhibited (Volkmar, 2001). Whether or not associated behavioral difficulties should be considered part of the syndrome of autism complicates an already clinically complex diagnostic issue.

This diagnostic uncertainty created by developmental level and comorbidity can pose considerable problems when trying to delineate the neurochemical features that comprise autistic disorder. Of course, the main goal of neurobiological research has been to reveal an all-encompassing etiology of autism that could account for the social, cognitive, and communication deficits that define the disorder. However, given the range of syndrome expression found within the diagnosis, it is hoped that certain biological measures may also have future diagnostic or prognostic utility.

This review seeks to investigate the current findings with regard to the neurochemical correlates of autism. While research has also examined other neurobiological aspects of the disorder (e.g., neuroanatomical), this article will be restricted to the chemical investigations in persons with autism. Neurochemical investigations of other neurobiological disorders (e.g., Parkinson’s disease, schizophrenia) have helped to shape etiological theories and guide future pharmacologic interventions. In some cases, research in neurochemistry has completely elucidated the cause of neurological disorders, as is the case with phenylketonuria (PKU). In this condition, the devastating
course of the disorder can be largely avoided by keeping phenylalanine out of the diet.

To date, neurochemical investigation has been most influenced by observed clinical responses to pharmacologic treatments; for example, the “dopamine hypothesis” of schizophrenia emerged from the significant improvements observed in schizophrenic patients who were receiving dopamine-blocking agents. Comparatively, research in the neurochemistry of autism has been somewhat less successful thus far, as there have been no known agents that can help to treat the core features of the disorder. Investigation into a wide array of chemical systems, including the monoamines, various neuropeptides, stress hormones, and amino acid neurotransmitters have been conducted, often with conflicting results. This review summarizes these investigations, and attempts to point out some of the more promising areas for future research.

2. Serotonin

Among all neurochemical investigations in autism, serotonin (5-hydroxytryptamine or 5-HT) has stimulated the most research and investigation. Serotonin is an indolamine that is derived from the essential amino acid tryptophan. Tryptophan is hydroxylated by tryptophan hydroxylase to create 5-hydroxytryptophan (5-HTP); this is the rate-limiting step in the synthesis of serotonin. Under normal physiological conditions, this enzyme is not fully saturated; therefore, increases in dietary tryptophan will usually result in increased levels of serotonin (Marsden, 1981). After tryptophan is converted into 5-HTP, it is finally decarboxylated (by 5-HTP decarboxylase) into serotonin.

Centrally, the cell bodies of serotonergic neurons are found in nine clusters, most of which are located in the raphe nuclei of the midbrain, pons, and medulla (Carlson, 2001). The two most important clusters with regard to behavior are found in the dorsal and medial raphe nuclei, both of which send projections to the cerebral cortex (Carlson, 2001; Marsden, 1981). The dorsal raphe nucleus also sends neuronal projections to the basal ganglia, an area of the brain important for the regulation of motor performance. The median raphe nucleus innervates the dentate gyrus, a part of the hippocampal formation (which is implicated in the storage of memory) (Carlson, 2001).

The behavioral effects of serotonin (5-HT) are complex. It regulates mood, eating, body temperature, and arousal, and it modulates pain sensitivity, sexual behavior, and hormone release. Initially, interest in 5-HT in autism arose from a consideration of its role in perception (Bauman & Kemper, 1994). The powerful effects of serotonergic hallucinogens, such as lysergic acid diethylamide (LSD), provided the impetus for early studies of 5-HT in autism. Further evidence for a role of serotonin in the expression of autistic disorder was provided by the finding that acute depletion of dietary tryptophan (the dietary precursor of serotonin) led to worsening of autistic symptomatology (McDougle, Naylor, Cohen, Aghajanian, et al., 1996a; McDougle, Naylor, Cohen, Volkmar, et al., 1996b).

More recently, serotonin’s role in early neural development has also been investigated as a possible etiological factor in the development of autistic disorder (Whitaker-Azimitia, 2001). Before assuming its role as a neurotransmitter in a mature brain, serotonin regulates both the development of serotonergic neurons as well as the development of target tissues, such as the hippocampus and the cerebral cortex. Whitaker-Azimitia (2001) suggested that high levels of serotonin during early development may cause a loss of serotonin terminals and subsequent neuronal development. Interestingly, researchers have shown that higher rates of autistic disorder occur in children who were exposed in utero to drugs known to increase serotonin levels, including cocaine (Davis et al., 1992; Kramer, Azmita, & Whitaker-Azmita, 1994) and possibly alcohol (Nanson, 1992).

These findings have provided the impetus for investigation of serotonergic abnormalities
in autistic disorder. Research has examined serotonergic functioning in the blood, cerebrospinal fluid, and, more recently, through the use of PET scans and genetic techniques.

2.1. Blood 5-HT

Early studies of blood serotonin in autism consistently found hyperserotonemia in one-third of people with autism; this has been replicated in more than 25 published studies (e.g., Shain & Freedman, 1961; Ritvo et al., 1970; Campbell et al., 1975; Takahashi, Kanai, & Miyamoto, 1976; McBride et al., 1998). The magnitude of this elevation is usually expressed as 5-HT in whole blood, and has typically been about 50% above normal levels (McBride et al., 1998). Subsequent research has established that more than 99% of whole blood serotonin is contained in the platelets (Anderson et al., 1987) and that platelet serotonin accounts for the hyperserotonemia in autism (Cook, Leventhal, & Freedman, 1988).

Animal research has indicated that hyperserotonemia can reduce the drive for social attachment by inhibiting separation distress (Chamberlain & Herman, 1990); this could perhaps account for the deficits in social relatedness found in individuals with autism. However, the cause and significance of these elevated levels of blood serotonin in autism remain unclear. One might assume that hyperserotonemia, because it is an abnormal finding, would serve as a marker for impairment or dysfunction. However, two studies have failed to show the expected inverse relationship between blood 5-HT and verbal expressive ability (Cook et al., 1990; Cuccaro, Wright, Abramson, Marsteller, & Valentine, 1993) in individuals with autism, so it is unknown how hyperserotonemia could play a role in autism’s expression.

In addition, it is difficult to draw conclusions about what these peripheral measurements tell us about the central differences in autism; nearly all of the 5-HT found in the blood is manufactured in the gut prior to absorption by platelets. Hyperserotonemia is not found exclusively in autism; it is also found in a variety of medical and neuropsychiatric disorders such as schizophrenia (Freedman, Belendiuk, Belendiuk, & Crayton, 1981), Huntington’s disease (Belendiuk, Belendiuk, & Freedman, 1980), and severe mental retardation (Hanley, Stahl, & Freedman, 1977; Pare, Sandler, & Stacey, 1960; Partington, Tu, & Wong, 1973). It is notable that the children first reported as having elevated blood serotonin in Shain and Freedman’s (1961) landmark paper were diagnosed not only with autistic disorder, but with severe mental retardation as well. It is likely that most reports of blood 5-HT are complicated by factors beyond the diagnosis of autistic disorder.

In an attempt to elucidate some of these variables, McBride et al. (1998) examined the effects of diagnosis (autistic versus mentally retarded versus typically developing), race, and puberty on blood levels of serotonin. They found among prepubertal children only, significant effects of diagnosis (with subjects with autism having higher 5-HT levels) and race (with white children having lower 5-HT levels than black or Latino youngsters, regardless of diagnosis). While these findings confirm that hyperserotonemia is more prevalent in children with autism, McBride et al. also stressed the importance of matching for pubertal status and race when conducting neurochemical research. It is possible that the hyperserotonemia reported in individuals with autism may have been overestimated due to failure to control for subject variables (McBride et al., 1998). Clearly, the study of whole blood serotonin is a complex issue; it is present in a variety of neurological disturbances, and it yields very little information about central serotonergic functioning. Therefore, it alone may not shed any light on the specific etiological mechanisms that are exclusive to autistic disorder.

2.2. CSF 5-HIAA
To assess central serotonergic functioning in autism, seven studies examined levels of 5-hydroxyindoleacetic acid (5-HIAA; serotonin’s major metabolite) in cerebral spinal fluid (CSF). Because nearly all 5-HT in the brain is metabolized to 5-HIAA before elimination, measurement of 5-HIAA in CSF provides a relatively accurate measure of central levels of serotonin, as it has been shown that it is not contaminated with 5-HT or 5-HIAA that is found elsewhere in the body (Anderson & Hoshino, 1997). The seven studies (Cohen, Shaywitz, Johnson, & Bowers, 1974; Cohen, Caparulo, Shaywitz, & Bowers, 1977; Winsberg, Sverd, Castells, Hurwie, & Perel, 1980; Gillberg, Svennerholm, & Hamilton-Helberg, 1983; Ross, Klykylo, & Anderson, 1985; Narayan, Srinath, Anderson, & Meundi, 1992) we were able to locate are summarized in Table 1.

Researchers have theorized that central serotonergic functioning is depressed in individuals with autism, as supported by the efficacy of serotonin reuptake inhibitors (SSRIs) in treating rituals and aggression in autism, at least in adults with autism (Cook, Rowlett, Jaselskis, & Leventhal, 1992; Gordon, State, Nelson, Hamburger, & Rapoport, 1993; McDougle et al., 1996a,b), as well as the finding that acute tryptophan depletion caused worsening of autistic symptomatology (McDougle et al., 1996a,b). However, the seven reports of measurements of 5-HIAA in CSF were consistent in showing no differences between autistic and control groups. These findings suggest that if there is a central serotonergic abnormality in autism, it does not involve a widespread or marked change in the turnover of 5-HT (Anderson, 1994).

### 2.3. Positron emission tomography (PET) studies

Recently, $\alpha-[^{11}\text{C}]$methyl-L-tryptophan ($[^{11}\text{C}]$AMT) has been developed as a tracer for measuring serotonin synthesis in the brain, using positron emission tomography (PET). PET allows one to observe the regional variance in serotonin synthesis and thus is a much more precise and informative measure of central serotonergic functioning in autism. To date, there have been two published studies using this method in subjects with autism. The first, conducted by Chugani et al. (1997) measured 5-HT synthesis in eight children with autism (seven boys, one girl; mean age 6.6 years) and five of their siblings (four boys, one girl; mean age 9.9 years). A diagnosis of autism was made using DSM-IV criteria, as well as meeting the criteria for autism using the Gilliam Autism Rating Scale (GARS) and the Childhood Autism Rating Scale (CARS).

Examination of the PET images revealed clear differences between the boys with autism and their siblings. In boys with autism, unilateral decreased 5-HT synthesis was found in the frontal cortex and thalamus and increased levels were found in the contralateral dentate nucleus of the cerebellum. For five of the seven boys, decreased accumulation was seen in the left frontal cortex and thalamus, accompanied by elevated accumulation on the right dentate nucleus. The remaining two boys had the mirror opposite image pattern of abnormality, with decreased accumulation seen in the right frontal cortex and thalamus with increased accumulation seen on the left dentate nucleus. This “reversed” pattern was not related to handedness or any other obvious subject characteristic. The frontal cortex, thalamus, and dentate nucleus are all connected via the dentatothalamocortical pathway, which is involved in sensory integration and speech production—skills that are significantly impaired in individuals with autistic disorder. In addition, the finding that 5-HT synthesis is elevated in one area and lowered in another could explain why measurements of 5-HIAA in CSF (discussed previously) have not shown any overall mean differences, as these differences in regional serotonin synthesis could in essence cancel one another out (Chugani et al., 1997).

A subsequent study by Chugani et al. (1999) examined the effects of age on serotonin synthesis in autistic and typically-developing subjects. This study had a larger sample size,
<table>
<thead>
<tr>
<th>Authors</th>
<th>Subjects</th>
<th>Medication free?</th>
<th>Criteria for diagnosis of autism</th>
<th>Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cohen et al. (1974)</td>
<td>9 autistic children, mean age = 7.7 years (S.D. = 2.8); 11 “atypical” children (not quite meeting criteria, classified as borderline psychotic), mean age = 8.34 (S.D. = 1.0)</td>
<td>Not reported</td>
<td>Clinical impression</td>
<td>No group differences</td>
</tr>
<tr>
<td>Cohen et al. (1977)</td>
<td>10 autistic children, mean age = 7.1 years (S.D. = 2.5); 10 nonautistic “psychotic” children, mean age 8.8 years (S.D. = 2.4)</td>
<td>Not reported</td>
<td>Clinical impression</td>
<td>No apparent abnormalities in autistic group</td>
</tr>
<tr>
<td>Winsberg et al. (1980)</td>
<td>8 autistic children, no other details available; no control subjects</td>
<td>Not reported</td>
<td>Clinical impression</td>
<td>No group differences</td>
</tr>
<tr>
<td>Gillberg et al. (1983)</td>
<td>13 autistic children, mean age 8.6 years (S.D. = 3.6); 13 age and gender matched typically-developing controls, mean age 8.4 years (S.D. = 3.5)</td>
<td>One subject on clomipramine</td>
<td>Rutter’s criteria</td>
<td>No group differences</td>
</tr>
<tr>
<td>Gillberg &amp; Svennerholm (1987)</td>
<td>25 autistic children (including 13 from 1983 study), mean age 8.1 years (S.D. = 4.3); 20 age and gender matched typically-developing controls (including 13 from 1983 study), mean age 8.3 years (S.D. = 4.3)</td>
<td>Two subjects on clomipramine</td>
<td>DSM-III, Rutter’s criteriab</td>
<td>No group differences</td>
</tr>
<tr>
<td>Ross et al. (1985)</td>
<td>9 autistic children, mean age 8.1 years (S.D. = 2.6); 10 control children (undergoing diagnostic myelography), mean age 10.8 years (S.D. = 4.7)</td>
<td>Yes</td>
<td>DSM-III</td>
<td>No group differences</td>
</tr>
<tr>
<td>Narayan et al. (1992)</td>
<td>17 autistic children, mean age 5.71 (S.D. = 2.75); 15 typically-developing controls, mean age 8.8 years (S.D. = 2.07)</td>
<td>Yes</td>
<td>DSM-III</td>
<td>No group differences</td>
</tr>
</tbody>
</table>

*Significantly lower.
* 5-HIAA = 5-hydroxyindolacetic acid.
*b Rutter’s criteria: (a) onset before 30 months, (b) impaired language, (c) impaired social development; (d) insistence on sameness.
involving 30 subjects with autism (24 boys, 6 girls, age range of 2.3–15.4 years), 8 of their siblings (6 boys, 2 girls, age range of 2.1–14.4 years), and 16 children with epilepsy (9 boys, 7 girls, age range 3 months to 13.4 years). A diagnosis of autism was rigorously fulfilled using DSM-IV criteria, as well as meeting criteria from the GARS, CARS, and the Autism Diagnostic Interview—Revised (ADI-R; Lord, Rutter, & Le Couteur, 1994). Examination of the PET images revealed that children without autism between the ages of 2 and 5 years showed high levels of 5-HT synthesis, which subsequently declined towards adult values between the ages of 5 and 14 years. Children with autism, on the other hand, did not show this decline in serotonin synthesis capacity over time; in fact, levels were significantly lower in these children at age 2–5 compared to controls and increased slightly with age (observed in both male and female subjects). This suggests that developmental regulation of serotonin synthesis may be involved in the pathogenesis of autism. As in the previous study, focal abnormalities were noted in boys with autism regardless of age, with increased serotonin synthesis seen in the frontal cortex and thalamus. The subjects with epilepsy also showed focal regions of increased 5-HT synthesis that were associated with the foci of their epilepsy. Focal differences were not observed in girls with autism, which could be due in part to gender differences in hemispheric specialization, but this requires further study.

2.4. Genetic studies

Motivated by the evidence for a genetic basis of autism (as evidenced by sibling and twin studies), researchers have begun to investigate potential candidate genes for the development and expression of autism. Some of this research has focused on the serotonin transporter gene (SLC6A4), which encodes for both the platelet and neuronal transport of 5-HT. Interest in this gene can be attributed to its possible role in the platelet hyperserotonemia in autism and to the clinical utility of SSRIs (which target these transporter proteins).

Two polymorphisms have been reported for SLC6A4: the deletion or short (s) allele and the long (l) allele (Tordjman et al., 2001). These polymorphisms are functionally significant; cell lines with sl or ss genotypes are shown to have approximately one-half the rates of 5-HT transport when compared to cell lines with ll genotypes (Lesch, Wolozin, Murphy, & Riederer, 1993). Theoretically, an “overactive” serotonin transporter (e.g., one with a ll genotype) would take 5-HT out of the synaptic cleft too quickly, causing a relative deficiency. This would be in line with the idea that areas of central serotonergic functioning are depressed in individuals with autism.

We located six studies examining polymorphisms of this gene in autism (Cook et al., 1997; Klauck, Poutska, Benner, Lesch, & Poutska, 1997; Maestrini et al., 1999; Persico et al., 2000; Tordjman et al., 2001; Yirmiya et al., 2001), and these are summarized in Table 2. Results do not provide clear evidence for consistent genotypic characteristics of people with autism: three studies failed to show any association of either polymorphism to autism, two studies showed preferential transmission of the long polymorphism, and one study showed preferential transmission for the short polymorphism.

At this point, it is difficult to determine the role of the serotonin transporter gene in autism. It is likely that autism will be characterized by genetic heterogeneity, and as is the
Table 2
Studies examining the serotonin transporter gene in autism

<table>
<thead>
<tr>
<th>Authors</th>
<th>Subjects</th>
<th>Criteria for diagnosis of autism</th>
<th>Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cook et al. (1997)</td>
<td>86 autistic probands, IQ &gt; 35; 86 biological mothers; 86 biological fathers</td>
<td>ADI-R; ADOS</td>
<td>Short variant preferentially transmitted to autistic children</td>
</tr>
<tr>
<td>Klauck et al. (1997)</td>
<td>65 autistic probands, IQ &gt; 35; 65 biological mothers; 65 biological fathers</td>
<td>ADI-R; ADOS, DSM-IV; ICD-10</td>
<td>Long variant preferentially transmitted to autistic children</td>
</tr>
<tr>
<td>Maestrini et al. (1999)</td>
<td>90 families with 174 “affected individuals”</td>
<td>Two diagnostic groups: Type 1: ADI-R including language delay; Type 2: could include PDD-NOS, Asperger's or autism without language delay</td>
<td>No group differences</td>
</tr>
<tr>
<td>Persico et al. (2000)</td>
<td>98 autistic probands; 98 biological mothers; 98 biological fathers</td>
<td>DSM-IV</td>
<td>No group differences</td>
</tr>
<tr>
<td>Tordjman et al. (2001)</td>
<td>46 autistic probands; 88 biological parents; 32 siblings</td>
<td>DSM-IV, ICD-10, ADI-R</td>
<td>No group differences, but found that severe autism was associated with short variant, and mild/moderate autism was associated with long variant.</td>
</tr>
<tr>
<td>Yirmiya et al. (2001)</td>
<td>34 autistic probands; 34 biological mothers; 34 biological fathers</td>
<td>DSM-III-R and DSM-IV, ADI-R</td>
<td>Long variant preferentially transmitted to autistic children</td>
</tr>
</tbody>
</table>

ADI-R, autism diagnostic interview - revised; ADOS, autism diagnostic observation schedule; PDD-NOS, pervasive developmental disorder - not otherwise specified.
case with many complex conditions, one gene may not be necessary or sufficient to produce the disorder (Yirmiya et al., 2001). Genetic heterogeneity would be consistent with the clinical heterogeneity in autism noted earlier. It is then notable that in one of the studies, while failing to find that any specific genotype conveyed risk for developing autistic disorder, the investigators found that the severity of autism was impacted by genotype, with greater transmission being observed in mild/moderate cases of autism and greater transmission observed in more severely impaired individuals (Tordjman et al., 2001). It is possible that while the serotonin transporter gene may not serve as a clear marker for autism, it may influence its behavioral phenotypic expression. Clearly, the study of serotonin in autism is a complex issue, and more research is needed in order to elucidate its possible role in autistic disorder.

2.5. Clinical/treatment implications

These potential abnormalities in serotonergic function naturally lead to hypotheses about treatment possibilities, and a number of strategies have been tried. Researchers have conducted investigations of L-Dopa and numerous studies of fenfluramine (both lower blood serotonin, presumably by relieving serotonergic-deficit up-regulation of serotonin production) in individuals with autism in hopes of producing clinical improvement. These studies failed to show consistent significant clinical benefit (Aman & Kern, 1989; Campbell, Anderson, & Small, 1990).

A large number of investigators have shown interest in the selective serotonin reuptake inhibitors (SSRIs; e.g., fluoxetine, paroxetine, citalopram) for various reasons. Beyond the “serotonin hypothesis” discussed above, these agents are also known to be effective as antidepressants and as effective anti-OCD (obsessive compulsive disorder) agents. The presence of restricted repetitive behavior in individuals with autism may justify the use of these medications for some practitioners. In fact, recent surveys of medication use in autism have reported that SSRIs are the most commonly-prescribed psychotropic medication in autism (Langworthy-Lam, Aman, & Van Bourgondien, 2002; Aman, Lam, & Collier-Crespin, 2003). Aman, Arnold, and Armstrong (1999) reviewed 47 case reports and studies of SSRIs and clomipramine, a serotonergic tricyclic antidepressant, in subjects with developmental disabilities (including autism). A large majority—but not all—of these reports suggested that these agents were often effective in managing perseverative behavior, including compulsions, stereotypies, and self injury (Aman et al., 1999). Further controlled research is needed, especially in pediatric samples, as it is possible that SSRIs may have different effects in younger people with autism. These differential effects may be related to the developmental variations in serotonin levels described above.

The atypical antipsychotics can be characterized as dopamine and serotonin receptor blockers. Although discussion of antipsychotics belongs more properly in the next major section, they deserve brief mention here. Recently, the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network (2002) assessed risperidone in a double blind, placebo controlled trial in 101 children chosen for high levels of irritability. Risperidone had a variety of therapeutic effects on both comorbid irritable behaviors and stereotypic/compulsive behavior.

3. Dopamine

Dopamine (DA) is a catecholamine that is synthesized from the dietary amino acid tyrosine. Once ingested, tyrosine is hydroxylated (by tyrosine hydroxylase) into L-dihydroxyphenylalanine (L-DOPA). This is the rate-limiting step of the synthesis of dopamine. L-DOPA is then converted to dopamine via the enzyme DOPA decarboxylase. Most DA-containing neurons lie in the midbrain; in particular, three important DA systems project from the substantia
nigra and the ventral tegmental area (Carlson, 2001). The nigrostriatal system has cell bodies located in the substantia nigra that project their axons to the neostriatum, an area that is involved in the control of movement. The mesolimbic system contains cell bodies in the ventral tegmental area and projects axons to several parts of the limbic system, including the nucleus accumbens (which plays a role in the reinforcing effects of certain stimuli), the amygdala (involved in emotion) and the hippocampus (involved in memory). Lastly, the mesocortical system also has its cell bodies in the ventral tegmental area; its axons, however, project to the prefrontal cortex, an area critical for higher-order functions, such as planning and formation of short-term memories (Carlson, 2001).

In general, the dopaminergic system is thought to affect a wide range of behaviors and functions, including cognition, motor function, brain-stimulation reward mechanisms, eating and drinking behaviors, sexual behavior, neuroendocrine regulation, and selective attention (Calne, Chase, & Barbeau, 1975; Costa & Gessa, 1977; Roberts, Woodruff, & Iversen, 1978). Interest in the role of DA in autism began with the observation that some DA blockers (i.e., antipsychotics) have been observed to be effective in treating some aspects of autism (Anderson & Hoshino, 1997). Specifically, the antipsychotics appear to alleviate hyperactivity, stereotypies, aggression, and self-injury (Young, Kavanagh, Anderson, Shaywitz, & Cohen, 1982). In addition, animal research has shown that stereotypies and hyperactivity can be induced by increasing dopaminergic functioning. These observations suggested that dopaminergic neurons could be overactive in autism, which led to studies of DA function. These were done by several methods, including blood and urine measurements of DA and its major metabolite, and measurements of this metabolite in CSF.

3.1. Blood and urine

Once released from the neuron, central DA is broken down into homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC). These substances, as well as DA itself, can be measured in both blood and urine. Measurements of urinary excretion of DA and HVA in autism have been essentially equivocal. Although some researchers have reported increased levels in autism (see Anderson & Hoshino, 1997 for a review), in a large study of autistic versus control subjects, no differences were found (Minderaa et al., 1989). In the one study that examined plasma levels of DA metabolite, no differences between autistic and control subjects were found (Minderaa et al., 1989). At this point, there does not appear to be any evidence of peripheral dopaminergic abnormalities of autism; in addition, it is not clear how these peripheral measurements relate to central dopaminergic functioning (Anderson & Hoshino, 1997). It has been suggested that only about 25% of blood or urine HVA is of central origin (Elchiasak, Polinsky, Ebert, Powers, & Kopin, 1978; Maas, Hattox, Greene, & Landis, 1980). Therefore, these measurements would only be capable of detecting widespread or marked alterations in the metabolism of DA in the brain (Anderson, 1994).

3.2. CSF HVA

In order to assess central dopaminergic functioning, measures of CSF HVA have been conducted. A total of seven studies in individuals with autism were located (Cohen et al., 1974, 1977; Winsberg et al., 1980; Gillberg et al., 1983; Gillberg & Svennerholm, 1987; Ross et al., 1985; Narayan et al., 1992) and are described in Table 3. In two of these studies (Gillberg et al., 1983; Gillberg & Svennerholm, 1987) approximately 50% of subjects with autism exhibited significantly elevated levels of CSF HVA. The remaining five studies showed no significant mean differences between control subjects and subjects with autism.
However, in the Cohen et al. studies (1974, 1977), though no significant group differences were found, the children with autism who displayed greater hyperkinesis and more severe stereotypies tended to have higher CSF HVA levels. These findings are similar to those found in studies examining symptom severity in Tourette’s disorder, where higher CSF HVA levels were correlated with more severe tics (Cohen et al., 1978). In addition, it has been found that CSF HVA levels are generally higher in males than in females (Leckman et al., 1980). Perhaps the higher CSF HVA levels in autism could be due in part to the markedly higher prevalence of the disorder in males (Young et al., 1982). At this point, whether or not central DA turnover is increased in autism is still a subject of debate (Gillberg, 1993; Narayan et al., 1992). These studies do not provide strong support for increased CSF HVA levels in autism. Taken together with the blood and urine studies, there is little evidence for differences between autistic and control subjects in neurochemical indexes in DA functioning.

3.3. Clinical/treatment implications

The more positive findings above led to early trials of dopamine-blocking agents, notably classical antipsychotic drugs, as possible treatment for core autistic symptoms. Some success has been demonstrated for repetitive, stereotyped behaviors, which, of all autistic symptoms, seem most closely linked theoretically with excess dopamine transmission (Schroeder, 1988; Ernst et al., 1999). Hyperactivity and aggression also were sometimes improved.

In the RUPP Autism Network (2002) study mentioned previously, treatment with risperidone caused reductions on all subscales of the Aberrant Behavior Checklist (Aman & Singh, 1994), with large reductions occurring on the Irritability, Stereotypic Behavior, and Hyperactivity subscales. Smaller, marginally-significant, effects were also observed on the Lethargy/Social Withdrawal and Inappropriate Speech (often manifested as echolalia) subscales. It is not clear whether risperidone truly influenced core symptoms or whether the changes seen in these core manifestations were a “halo” effect of major symptom reduction in acting out symptoms. McDougle et al. (in press) reported on other (“secondary”) measures from the RUPP study. They reported significant drug-related
Table 3
Studies examining HVA* levels in cerebral spinal fluid

<table>
<thead>
<tr>
<th>Authors</th>
<th>Subjects</th>
<th>Medication free?</th>
<th>Criteria for diagnosis of autism</th>
<th>Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cohen et al. (1974)</td>
<td>9 autistic children, mean age = 7.7 years (S.D. = 2.8); 11 “atypical” children (not quite making criteria, classified as borderline psychotic), mean age = 8.34 (S.D. = 1.0)</td>
<td>Not reported</td>
<td>Clinical impression</td>
<td>No group differences</td>
</tr>
<tr>
<td>Cohen et al. (1977)</td>
<td>10 autistic children, mean age = 7.1 years (S.D. = 2.5); 10 nonautistic “psychotic” children, mean age 8.8 years (S.D. = 2.4)</td>
<td>Not reported</td>
<td>Clinical impression</td>
<td>No group differences</td>
</tr>
<tr>
<td>Winsberg et al. (1980)</td>
<td>8 autistic children, no other details available; no control subjects</td>
<td></td>
<td>Clinical impression</td>
<td>No group differences</td>
</tr>
<tr>
<td>Gillberg et al. (1983)</td>
<td>13 autistic children, mean age 8.6 years (S.D. = 3.6); 13 age and gender matched typically-developing controls, mean age 8.4 years (S.D. = 3.5)</td>
<td>One subject on clomipramine</td>
<td>Rutter’s criteria</td>
<td>Mean HVA increased by 48% in autistic subjects</td>
</tr>
<tr>
<td>Gillberg &amp; Svennerholm (1987)</td>
<td>25 autistic children (including 13 from 1983 study), mean age 8.1 years (S.D. = 4.3); 20 age and gender matched typically-developing controls (including 13 from 1983 study), mean age 8.3 years (S.D. = 4.3)</td>
<td>Two subjects on clomipramine</td>
<td>DSM-III, Rutter’s criteria</td>
<td>Mean HVA increased by 54% in autistic subjects</td>
</tr>
<tr>
<td>Ross et al. (1985)</td>
<td>9 autistic children, mean age 8.1 years (S.D. = 2.6); 10 control children (undergoing diagnostic myelography), mean age 10.8 years (S.D. = 4.7)</td>
<td>Yes</td>
<td>DSM-III</td>
<td>No group differences</td>
</tr>
<tr>
<td>Naraynn et al. (1992)</td>
<td>17 autistic children, mean age 5.71 (S.D. = 2.75); 15 typically-developing controls, mean age 8.8 years (S.D. = 2.67)</td>
<td>Yes</td>
<td>DSM-III</td>
<td>No group differences</td>
</tr>
</tbody>
</table>

*a HVA = homovanillic acid.

b Rutter’s criteria: (a) onset before 30 months, (b) impaired language, (c) impaired social development, (d) insistence on sameness.
improvements in restricted, repetitive, and stereotyped patterns of behavior but not in social interactions and communication. At this stage, it is not clear whether longer exposure to risperidone or other atypical antipsychotics may produce lasting changes in core manifestations of autism.

4. Norepinephrine

Norepinephrine (also known as noradrenaline) is a catecholamine that is synthesized from DA through the action of the enzyme DA beta-hydroxylase. Nearly every region of the brain receives input from noradrenergic neurons (Carlson, 2001). The cell bodies of the most important system are located in the locus coeruleus, which is located in the dorsal pons. The projections of this area are distributed widely throughout the brain, and activity of these systems is thought to play a critical role in attention, filtering of irrelevant stimuli, stress response (e.g., “fight or flight” response), anxiety, and memory (Amaral & Sinnamon, 1977; Moore & Bloom, 1979). Since many of these functions are impaired in individuals with autism, researchers have investigated whether noradrenergic functioning within the diagnosis is altered. Noradrenergic activity has been assessed in autism via measurement of norepinephrine (NE) and its central and/or peripheral metabolites in blood, urine, and CSF.

4.1. Blood studies

Noradrenergic function can be measured in the blood as NE itself, and as its principal central metabolite, 3-methoxy-4-hydroxyphenylglycol (MHPG). Unlike some of the other neurotransmitter systems, central and peripheral noradrenergic systems are tightly coupled (Schildkraut et al., 1978) with blood and CSF concentrations being highly correlated (Raskind, Peskind, Halter, & Jimerson, 1984; Roy, Pickar, DeJong, Karoum, & Linnoila, 1988; Ziegler, Wood, Lake, & Kopin, 1977). As a result, peripheral measurements may give a good perspective on central noradrenergic functioning. A total of seven studies examining NE system levels in the blood were located; these are listed in Table 4. Five of these, all of which measured NE, showed higher concentrations in subjects with autism as compared with controls (Lake, Ziegler, & Murphy, 1977; Launay et al., 1987; Cook et al., 1990; Leventhal, Cook, Morford, Raviatz, & Freedman, 1990; Leboyer, Bouvard, & Launay, 1992). The results of the remaining two studies, which measured MHPG levels, failed to show any differences between individuals with autism and normal controls (Young et al., 1981; Minderaa, Anderson, Volkmar, Akkerhuis, & Cohen, 1994).

4.2. Urine studies

Studies examining excretion of NE and its metabolites in individuals with autism have yielded inconsistent findings. When analyzing excretion rates of norepinephrine, researchers have found increased (Barthelemy et al., 1988), decreased (Young, Cohen, Brown, & Caparulo, 1978), as well as equivocal (Launay et al., 1987; Martineau,
<table>
<thead>
<tr>
<th>Study</th>
<th>Participants</th>
<th>Controls</th>
<th>Results</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lake et al (1977)</td>
<td>11 autistic children, mean age 15 years (S.D. = 2.0); 12 typically-developing controls, matched for age, mean age 15 years (S.D. = 1.0)</td>
<td>No Kanner’s Criteria</td>
<td>↑ In autistic subjects</td>
<td></td>
</tr>
<tr>
<td>Launay et al. (1987)</td>
<td>22 autistic children, mean age 10.5; 22 typically developing controls, matched for age and sex</td>
<td>Two subjects on meds: thioridazine and pericytazine, tested in vitro to have no effect on NE</td>
<td>DSM III</td>
<td>↑ In autistic subjects</td>
</tr>
<tr>
<td>Leventhal et al. (1990)</td>
<td>39 autistic children, mean age 8.99 (S.D. = 4.4); 32 siblings of autistic children, mean age 11.2 years (S.D. = 5.3); 78 parents of autistic children, mean age 38.7 years (S.D. = 6.5); 98 unrelated adult controls, mean age 28.2 (S.D. = 8.4)</td>
<td>Yes</td>
<td>DSM III</td>
<td>↑ In autistic subjects</td>
</tr>
<tr>
<td>Leboyer et al. (1992)</td>
<td>All subjects autistic with severe MR and SIB: 1 autistic female, aged 12 years; 3 autistic males, aged 4 years, 12 years, and 19 years</td>
<td>One subject on a neuroleptic</td>
<td>DSM III</td>
<td>↑ In autistic subjects</td>
</tr>
<tr>
<td>Plasma MHPG*</td>
<td>Young et al. (1981)</td>
<td>No DSM III</td>
<td>No difference</td>
<td></td>
</tr>
<tr>
<td>Minderaa et al. (1994)</td>
<td>40 autistic individuals, mean age 20.0 years (S.D. = 4.4); 20 age- and sex-matched typically developing controls, mean age 19.6 years (S.D. = 6.7)</td>
<td>No, but grouped according to drug use; no effect</td>
<td>DSM III</td>
<td>No difference</td>
</tr>
</tbody>
</table>

↑ Significantly higher.

* MHPG = 3-methoxy-4-hydroxyphenylglycol (principal central metabolite of norepinephrine).

Table 4. Studies examining noradrenergic functioning

Barthelemy, Jouve, Muh, & Lelord, 1992; Minderaa et al., 1994; Croonenberghs et al., 2000)
concentrations in individuals with autism when compared to control subjects. Other studies looking at excretion rates of MHPG have reported decreased (Young et al., 1978; Barthelemy et al., 1988) and normal (Launay et al., 1987; Minderaa et al., 1994) activity in subjects with autism. Lastly, studies examining levels of norepinephrine’s predominant peripheral metabolite, vanillylmandelic acid (VMA) did not produce significant differences between autistic and control subjects (Minderaa et al., 1994).

4.3. Studies of CSF

Two studies measuring levels of MHPG in cerebrospinal fluid were located (Young et al., 1981; Gillberg & Svennerholm, 1987). Both of these studies used DSM-III criteria to diagnose autism, and neither study showed any significant difference between autistic and control subjects. Overall, these results indicate that the only consistent abnormal finding with regard to noradrenergic functioning in autism is elevated plasma norepinephrine levels. All other measurements suggest that noradrenergic functioning is not greatly altered within the disorder. Initially, the elevated plasma NE may seem to be in conflict with all of these other null findings. However, when one considers the time frame of the various measures, these seemingly disparate findings may be reconciled. It is known that plasma NE has an extremely short half-life and largely reflects the state of sympathetic arousal at the time of blood drawing (Minderaa et al., 1994). The other measurements of blood, urine, and CSF are time-averaged indices of noradrenergic functioning. It is then possible that baseline NE functioning is normal in subjects with autism, but that clinical procedures (such as drawing blood) may lead to hyperarousal and a heightened sympathetic response (Minderaa et al., 1994; Cook, 1990), thus resulting in temporarily higher levels of NE in the blood. Collectively, these results suggest little role for NE in the expression and etiology of autistic disorder.

4.4. Clinical/treatment implications

Consistent with the paucity of findings above, benefit from norepinephrine agonists and antagonists in autism has been sparsely reported, inconsistent, and clouded with adverse events. Tricyclic antidepressants such as imipramine, desipramine, and nortriptyline are all norepinephrine reuptake blockers, although they have other actions, such as dopamine presynaptic reuptake blockade. Gordon et al. (1993) compared placebo, desipramine, and clomipramine in 24 subjects with autistic disorder. Both desipramine and clomipramine reduced hyperactivity, whereas clomipramine had additional effects on stereotypic, compulsive, and ritualistic behavior. Thus the adrenergic effect seemed to be confined to hyperactivity, whereas clomipramine’s effect on perseverative behavior appears to be due to its serotonergic effects (discussed previously in the serotonin section). McDougle and Posey (2003) noted that alpha 2 agonists like clonidine and quanfacine, which dampen noradrenaline action, are sometimes helpful for managing hyperactivity in young people with autism. However, the drugs do not appear to affect any of the core manifestations of autism. Postsynaptic beta blockers, like propranolol and nadolol, are sometimes helpful for managing aggression, self injury, and agitation (Fraser, Ruedrich, Kerr, & Levitas, 1998), but again they appear to have no consistent effect on manifestations of autism.

5. Acetylcholine

Acetylcholine (ACh) is the neurotransmitter found at the neuromuscular junction, in autonomic nervous system ganglia, and in multiple sites in the CNS (Kandel, Schwartz, & Jessel, 1995). In the brain, three systems have been of interest to neuroscientists: the dorsolateral pons (involved in REM sleep), the basal forebrain (which activates areas of the cerebral cortex and
facilitates learning), and the medial septum (which projects to the hippocampus, an area involved in memory). There are two kinds of ACh receptors: nicotinic and muscarinic. Both are found in the brain, though muscarinic receptors are more prevalent. Overall, the cholinergic system has been referred to as an “action system” that helps develop the ability to focus on the environment and achieve a coherent behavioral response (Stahl, 1996).

The role of acetylcholine deficits in autism has not been explored until recently. However, a report of neuropathological abnormalities in cholinergic neurons located in the basal forebrain of individuals with autism has generated interest in the study of acetylcholine (Bauman & Kemper, 1994). Since the cholinergic system has been shown to play a role in the development and function of cognitive abilities, it has been hypothesized that a disruption in this system could be linked to the cognitive deficits that often accompany autism (e.g., problems with attention, learning). At this point, investigators have only begun to examine ACh function in autism, via postmortem studies of acetylcholine function and medication studies, which are summarized below.

5.1. Postmortem studies

A series of three studies examining cholinergic activity in autism postmortem were located (Perry et al., 2001; Lee et al., 2002; Martin-Ruiz et al., 2004). In the first of these studies, Perry et al. (2001) compared the brains of individuals with autism to the brains of individuals with mental retardation, as well as to the brains of typically-developing individuals matched for age. Measures of cholinergic enzyme markers (acetylcholinetransferase and acetylcholinesterase) showed no significant differences between groups. However, analysis of receptor binding revealed a large (65–75%) and significant reduction in ACh binding in nicotinic (alpha 4 and beta 2) receptors in the parietal and frontal cortices in autism. Significant reductions (30%) in muscarinic (M1) receptors in the parietal cortex were also found in individuals with autism. Subsequent research has assessed further potential abnormalities of nicotinic receptors in autism (Lee et al., 2002; Martin-Ruiz et al., 2004). However, it is unclear how these differences might be related to the etiology of autism. It has been suggested that the findings of decreased nicotinic receptor function may provide a cue for possible medication interventions, as nicotinic receptor agonists are known to enhance attentional function (Lee et al., 2002).

5.2. Clinical/treatment implications

At this stage, the best strategy for boosting the action of ACh in the brain is to inhibit agents that metabolize ACh. Several drugs have been developed to fight the brain-wasting that occurs with Alzheimer’s disorder. They work to increase central ACh activity by leaving it in the synaptic cleft longer before it is broken down by enzymes. Researchers have begun to investigate the use of acetylcholinesterase inhibitors, including donepezil (Chez, Tremb, Nowinski, & Field-Chez, 2001; Hardan & Handen, 2002), galantamine (Niederhofer, Staffen, & Mair, 2002), and rivastigmine tartate (Chez, Aimonovitch, Buchanan, Mrazek, & Tremb, 2004) in autism. Two of these investigations were double-blind, placebo-controlled studies, and both reported improvements with active treatment (Niederhofer et al., 2002; Chez et al., 2001). Niederhofer et al. reported improvements in irritability, whereas Chez et al. (2001) reported improvements in symptoms of autism and in language. Hardan and Handen (2002) treated eight patients having autism with donepezil in an open trial. Four of them were regarded as showing substantial improvement, with behavioral changes largely occurring in the areas of irritability and hyperactivity. These results provide preliminary evidence for the use of acetylcholinesterase inhibitors in autism, and they suggest that further study of the cholinergic system in autism is warranted.
6. Oxytocin

Oxytocin (OT) is a peptide synthesized in the paraventricular nucleus (PVN) and the supraoptic nucleus (SON) in the brain. Cells in the PVN that synthesize oxytocin project diffusely throughout the brain and the brainstem (Sofroniew & Weindl, 1981). It has also been found that receptors for oxytocin are located throughout the limbic system in the forebrain and in the autonomic centers in the brainstem (Barberis & Tribollet, 1996). These observations strongly suggest that OT acts centrally as a neuromodulator (Insel, O’Brien, & Leckman, 1999).

Behaviorally, the OT system has been implicated in maternal behavior, infant separation distress, sexual behavior, and in the development of social attachments (Insel et al., 1999; Insel, 1992). Animal research has provided much of the groundwork for these findings; for example, in monogamous prairie voles, oxytocin was shown to be both necessary and sufficient for the normal development of partner selection in females (Insel & Hulihan, 1995). If an oxytocin antagonist is administered to these species, pair bonding will not occur. Conversely, if oxytocin is administered centrally, pair bonding is facilitated, even in the absence of mating.

Given that social impairment is a primary symptom of autistic disorder, researchers have begun to investigate whether or not the OT system is dysfunctional in individuals with autism. However, research in this area is in its infancy. To date, there has been one study examining blood levels of oxytocin (Modahl et al., 1998). A total of 29 boys with autism and 30 controls between the ages of 6 and 11 were studied; this involved a blood draw, as well as a series of social and developmental measures. As a group, subjects with autism had significantly lower levels of oxytocin. Moreover, when the relationships of OT to subject characteristics were examined, two interesting trends emerged.

First, OT plasma levels were positively associated with age for normal children, but not for children with autism. The rise in OT in older children is consistent with the surge of other hormone systems that increase before the onset of puberty in normal children (Modahl et al., 1998). The lack of an increase in OT in children with autism may reflect delay in physical maturation in this group (Campbell et al., 1980; Simon & Gillies, 1976) or a failure of the trigger for developmental increase in OT. Second, and perhaps more interestingly, in normal children oxytocin levels were positively related to socialization skills. However, oxytocin levels were negatively related to socialization skills in children with autism (Modahl et al., 1998). This finding suggests that a simple OT deficit model in autism is not adequate. Rather, these lower blood oxytocin levels may reflect compensatory mechanisms for underlying abnormalities in receptors or substances upstream from OT, resulting in secondary dysregulation (Modahl et al., 1998). These studies can be viewed as preliminary suggestive evidence that oxytocin dysregulation may play a role in the disorder.

6.1. Clinical/treatment implications

The intriguing findings above raise hope of finding some neurochemical treatment that might directly address the social impairment of autism, which, in contrast to stereotyped behavior, has generally been resistant to psychopharmacology. Recently, data were presented from a study in which 15 adults with autism or Asperger’s disorder were infused with either synthetic OT (pitocin) or placebo in a double-blind crossover fashion (Hollander et al., 2003). Administration of oxytocin resulted in significant decreases in repetitive behaviors in subjects with autism. Social impairment was not assessed. More investigation of this hormone would be helpful in determining if it has a therapeutic role to play. Unfortunately, synthetic OT (pitocin) is only available in an injectable vehicle, which impedes efforts to assess what its effects may be in more real-life settings. Furthermore, having administration confined to injections would seriously limit the practical
utility of most agents with short times of action.

7. Endogenous opioids

Endogenous opioids are peptides that exert effects on the central nervous system, acting as neuromodulators. There are three distinct types: beta-endorphins, enkephalins, and dynorphin. Each type of opioid has a different affinity for a certain receptor subtype: beta-endorphins for mu receptors (implicated in analgesia and euphoria), the enkephalins for mu and delta (less understood, perhaps associated in analgesia and reinforcement), and dynorphins for kappa receptors (implicated in spinal analgesia).

Opioid peptides appear to be endogenous ligands for the receptors activated by morphine and related compounds (Anderson & Hoshino, 1997). Some of the behavioral effects of opiate administration include (a) insensitivity to pain, (b) affective lability, (c) stereotyped behaviors, and (d) reduced socialization (Kalat, 1978; Panksepp, 1979; Sandman, 1991, 1992). Since these effects are consistent with some of the symptoms of autism, researchers have theorized that an increase in opioid functioning could play a role in the disorder (e.g., Panksepp, 1979; Anderson, 1994). This hypothesis has been tested by assessing opioid levels (beta-endorphin, in particular) in the blood and CSF, as well as by the administration of opiate agonists.

7.1. Blood and CSF studies

Previous studies examining levels of endogenous opioids in the blood have yielded inconsistent results. These studies are summarized in Table 5. Nine studies were located, all of which examined levels of beta-endorphin (BE). Four groups of investigators reported elevated levels in subjects with autism, while four other groups reported decreased levels when compared to control groups. Three studies reported equivocal findings. It is notable that BE in the plasma is derived from the pituitary, and does not cross the blood-brain barrier. Therefore, it is not a clear indicator of central functioning; rather, elevated levels of BE in the blood appear to reflect acute stress (Tordjman et al., 1997; Anderson & Hoshino, 1997). It is then possible that any elevated BE in blood could be a result of the stress of the blood draw itself, and therefore, not give a sense of baseline BE levels.

Studies of endogenous opioids in cerebrospinal fluid are less common (see Table 5). Three studies were located, one of which indicated elevated levels when compared to controls (Ross, Klykylo, & Hitzemann, 1987), one which displayed decreased levels (Gillberg, Hagberg, Witt-Engerstom, & Eriksson, 1990) and one which showed levels similar to controls (Nagamitsu, 1993). It is difficult to draw any conclusions from these studies, especially considering the small number of subjects employed and the use of control subjects that may not be representative [e.g., using normal adults as a control group for children with autism (Gillberg et al., 1990)].

At this point, the study of opioid activity in autism has produced little of clinical relevance beyond the symptomatic reduction of self-injury and hyperactivity in some subjects.

7.2. Clinical/treatment implications

A number of investigators have examined the effects of opiate antagonists (naloxone and naltrexone) in individuals with autism, under the assumption that opioid hyperfunction may be an important mediator of autistic behavior. Most of these studies used naltrexone, and the effects on core symptoms of autism were modest, at best (Sandman, 1988; Herman et al., 1986; Campbell et al., 1989; Leboyer et al., 1992; Campbell et al., 1993). However, some studies showed a reduction in self-injurious behavior. The inconsistent benefit (varying from patient to patient) of opiate antagonists for self-injurious behavior is worth considering even if there is no benefit for core
autistic symptoms. Self injury resistant to behavioral treatment is such a severe problem when it occurs that any treatment that can assist in its management on a case-by-case basis must be regarded as an asset. One serendipitous finding in the studies that looked for an effect of naltrexone on autism was a fairly consistent effect in reducing symptoms of hyperactivity and impulsive behavior (Aman & Langworthy, 2000). If confirmed and found to be safe, this could be an important use of naltrexone in this very vulnerable population.
Table 5
Studies examining beta-endorphin levels in autism

<table>
<thead>
<tr>
<th>Authors</th>
<th>Subjects</th>
<th>Drug free?</th>
<th>Criteria for diagnosis of autism</th>
<th>Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measurements in blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weizman et al. (1984)</td>
<td>10 autistic subjects, aged 7-17 years; 12 chronic schizophrenic subjects, matched for age and sex; 11 normal control subjects, matched for age and sex</td>
<td>No</td>
<td>DSM-III</td>
<td>↓ Levels in subjects with autism</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weizman et al. (1988)</td>
<td>22 autistic subjects, mean age 16.3 years (S.D. = 5.7); 22 chronic schizophrenic subjects, matched for age and sex; 22 normal control subjects, matched for age and sex</td>
<td></td>
<td>DSM-III</td>
<td>↓ Levels in subjects with autism (medicated and unmedicated)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sandman et al. (1991)</td>
<td>8 autistic subjects, mean age 26 years (S.D. = 3.0); 13 institutionalized adults with MR, mean age 24 years (S.D. = 6.0); 17 normal control subjects, mean age 29 years (S.D. = 11.0)</td>
<td>Not reported</td>
<td>AAMD</td>
<td>↑ Compared to MR, ↓ compared to normal controls</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leboyer et al. (1992)</td>
<td>4 individuals with autism; all with severe MR and self-injury; (1 female, aged 12 years; 3 males, aged 4 years, 12 years, and 19 years)</td>
<td></td>
<td>DSM-III</td>
<td>↑ Levels compared to norms</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ernst et al. (1993)</td>
<td>5 individuals with autism, all male, mean age 5.86 years (S.D. = 1.54)</td>
<td>Yes</td>
<td>DSM-III-R</td>
<td>Not compared to controls, no correlation between severity or self injury</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leboyer et al. (1994)</td>
<td>67 individuals with autism, aged 3-23 years (S.D. = 4.3); 67 normal control subjects, matched for age and sex; 22 girls with Rett’s syndrome, aged 4-15 years (S.D. = 3.4)</td>
<td>No</td>
<td>DSM-III-R; ICD-10; ADI</td>
<td>Altered fragments in autism</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bouvard et al. (1995)</td>
<td>10 individuals with autism</td>
<td>No</td>
<td>DSM-III-R; ADI</td>
<td>Altered fragments in autism</td>
</tr>
<tr>
<td>Willemsen-Swinkles, Buitelaar,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weltsen, Thijsen, &amp; Van Engeland (1996)</td>
<td>24 autistic individuals (some with self injury); 9 individuals with self injury</td>
<td>No</td>
<td>DSM-III-R</td>
<td>↑ Levels in individuals with severe self injury</td>
</tr>
<tr>
<td>Study</td>
<td>Sample Description</td>
<td>Methodology</td>
<td>Reference</td>
<td>Note</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>-------------</td>
<td>-------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Tordjman et al. (1997)</td>
<td>48 individuals with autism, mean age 10 years (S.D. = 7.1); 16 individuals with mental retardation, mean age 8.5 years (S.D. = 4.7); 26 normal control subjects, mean age 14.6 years (S.D. = 8.1)</td>
<td>Yes</td>
<td>DSM-III-R</td>
<td>† Levels in subjects with autism</td>
</tr>
<tr>
<td>Measurements in cerebral spinal fluid</td>
<td>9 individuals with autism; 9 normal control subjects, matched for age and sex</td>
<td>Not known</td>
<td>Not known</td>
<td>† Levels in subjects with autism</td>
</tr>
<tr>
<td>Ross et al. (1987)</td>
<td>31 children with autism; 8 girls with Rett's syndrome; 5 infants with infantile spasms; 51 normal adult controls</td>
<td>Two subjects on carbamazepine</td>
<td>DSM-III-R</td>
<td>† Levels in subjects with autism and Rett's syndrome</td>
</tr>
<tr>
<td>Gillberg et al. (1990)</td>
<td>19 individuals with autism, mean age 51 months (S.D. = 14); 3 girls with Rett's syndrome; 6 babies with infantile spasms, aged 3-15 mo; 23 normal control subjects, aged 0-10 years</td>
<td>Yes, for autistic subjects</td>
<td>DSM-III-R</td>
<td>No differences</td>
</tr>
</tbody>
</table>

† Significantly increase; AAMD = American Association on Mental Deficiency.
8. Cortisol

Cortisol is a glucocorticoid that is released by the adrenal cortex in response to stress. Its secretion is controlled by the hormone adrenocorticotropic (ACTH), which is released from the pituitary. ACTH release, in turn, is under the control of corticotropin-releasing factor (CRF) which is produced in the hypothalamus. Normally, cortisol limits its own release via a feedback loop, by suppressing the release of CRF and ACTH. Abnormalities in this feedback mechanism have been studied extensively in depression, using the dexamethasone suppression test (DST; Gwirtsman, Gerner, & Sternbach, 1982).

Cortisol functioning in autism has been evaluated to assess the theory that some of the related behavioral disturbances could be due to a chronic heightened level of activation and hyperarousal, which might result in elevated levels of this stress hormone. Eleven studies (summarized in Table 6) have examined basal levels of cortisol, ACTH, or response to dexamethasone. Five studies using blood measurements of cortisol or ACTH found no differences between autistic and control subjects, which suggests that baseline levels of cortisol functioning are not greatly altered in autism. The largest study, involving 48 individuals with autism, did find significantly elevated levels of ACTH and normal levels of cortisol (Tordjman et al., 1997). It has been established that plasma ACTH is a good marker for acute stress. Cortisol, on the other hand, has a longer half-life and has a significantly longer latency to respond to stress, providing a better measure for basal stress levels (Tordjman et al., 1997). Therefore, rather than providing evidence for a chronic hyperarousal state, these results suggest that individuals with autism exhibit a heightened stress response to experimental procedures, such as the drawing of blood. These results are in agreement with observations of elevated blood NE and BE discussed previously.

It is interesting, however, that the two studies involving DST have shown that some individuals with autism do not display normal suppression of cortisol. This finding may provide further evidence for abnormalities in serotonergic or noradrenergic functioning, as workers have suggested that these neurotransmitters may have a regulatory effect on ACTH and CRF release (Butterweck, Winterhoff, & Herkenham, 2001; Maccari et al., 1992; Stokes & Sikes, 1987). Further research is needed to clarify these findings.

8.1. Clinical/treatment implications

Other areas of medicine make use of agents that mimic, suppress, or regulate the HPA axis. Unfortunately, such strategies carry considerable risk, so the benefits would have to be considerable to justify this as a therapeutic approach. We were unable to find therapeutic trials of medications that affect cortisol release in subjects with autism.

9. Amino acid neurotransmitters: glutamate and GABA

Glutamate and gamma-aminobutyric acid (GABA) are the two transmitter substances that are linked to widespread synaptic communication in the CNS. Glutamate is the principal excitatory transmitter substance in the brain and spinal cord, whereas GABA is responsible for most of the inhibitory communication in the brain (Carlson, 2001; Kandel
Table 6
Measures of cortisol functioning in autism

<table>
<thead>
<tr>
<th>Authors</th>
<th>Subjects</th>
<th>Medication free?</th>
<th>Criteria for diagnosis</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Plasma ACTH</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brambilla et al. (1969)</td>
<td>8 psychotic subjects (who presented with ‘autism, delayed speech, stereotypies, alteration of instincts’) aged 5–13 years; compared to normal values (no normal control subjects)</td>
<td>Not reported</td>
<td>Clinical impression</td>
<td>No differences</td>
</tr>
<tr>
<td>Bouvard et al. (1995)</td>
<td>10 autistic subjects, aged 5–14 years; no control group</td>
<td>Yes</td>
<td>DSM-III-R, ADI</td>
<td>↓ Levels than normal values</td>
</tr>
<tr>
<td>Tordjman et al. (1997)</td>
<td>48 autistic subjects, mean age 10.0 years (S.D. = 7.1); 16 mentally-retarded subjects, mean age 8.5 (S.D. = 4.7); 26 “normal control” subjects, mean age 14.6 (S.D. = 8.1)</td>
<td>Yes</td>
<td>DSM-III-R, ADOS</td>
<td>↑ Levels in subjects with severe autism</td>
</tr>
<tr>
<td><strong>Plasma Cortisol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goodwin et al. (1971)</td>
<td>15 autistic subjects; compared to siblings</td>
<td>Not known</td>
<td>Clinical impression</td>
<td>No differences</td>
</tr>
<tr>
<td>Maher et al. (1975)</td>
<td>11 autistic children, aged 4–13 years; 11 mentally-retarded children, matched for age and sex</td>
<td>Diazepam for sedation, no other meds</td>
<td>Clinical impression</td>
<td>No differences</td>
</tr>
<tr>
<td>Yamazaki et al. (1975)</td>
<td>7 autistic children, aged 6–10 years; 2 children with Heller’s syndrome</td>
<td>Not reported</td>
<td>Clinical impression</td>
<td>Abnormal rhythm found in autistic subjects (usually high in the AM)</td>
</tr>
<tr>
<td>Hill et al. (1977)</td>
<td>6 autistic children; control group (other info not found)</td>
<td>Not known</td>
<td>Clinical impression</td>
<td>Lower level than controls, abnormal rhythm</td>
</tr>
<tr>
<td>Sandman et al. (1991)</td>
<td>8 autistic subjects, mean age 26 years (S.D. = 3.0); 13 institutionalized patient control subjects, mean age 24 years (S.D. = 6.0); 17 “normal control” subjects, mean age 29 years (S.D. = 11.0)</td>
<td>Not reported</td>
<td>Clinical impression (AAMD)</td>
<td>No differences</td>
</tr>
<tr>
<td>Tordjman et al. (1997)</td>
<td>48 autistic subjects, mean age 10.0 years (S.D. = 7.1); 16 mentally-retarded subjects, mean age 8.5 (S.D. = 4.7); 26 “normal control” subjects, mean age 14.6 (S.D. = 8.1)</td>
<td>Yes</td>
<td>DSM-III-R, ADOS</td>
<td>No differences</td>
</tr>
<tr>
<td>Authors</td>
<td>Subjects</td>
<td>Medication free?</td>
<td>Criteria for diagnosis</td>
<td>Results</td>
</tr>
<tr>
<td>-------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>------------------</td>
<td>------------------------</td>
<td>------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Dexamethasone suppression test (DST)</td>
<td></td>
<td></td>
<td></td>
<td>11/13 non-suppressors 3/11 high functioning and 8/8 low functioning autistic patients non-suppressors (as compared to 1/15 MR and none of the schizophrenic or normal controls)</td>
</tr>
<tr>
<td>Jensen et al. (1985)</td>
<td>13 autistic subjects</td>
<td>Not known</td>
<td>Not known</td>
<td>11/13 non-suppressors</td>
</tr>
<tr>
<td>Hashimoto et al. (1987)</td>
<td>10 autistic subjects; 26 &quot;normal control&quot; subjects; 19 schizophrenic subjects; 15 mentally-retarded subjects</td>
<td>Not known</td>
<td>Not known</td>
<td>3/11 high functioning and 8/8 low functioning autistic patients non-suppressors (as compared to 1/15 MR and none of the schizophrenic or normal controls)</td>
</tr>
</tbody>
</table>

† Significantly higher; †† Significantly lower; ADI = Autism Diagnostic Interview; ADOS = Autism Diagnostic Observation Schedule.
et al., 1995). Glycine is the principle inhibitory transmitter in the spinal cord and lower brain stem. These substances are widely produced in the central nervous system by the cell’s metabolic processes, and their effects are very widespread; there are few, if any, areas in the brain that do not receive input from glutamate and GABA (Carlson, 2001). Research in these two neurotransmitters has been tightly-linked, as GABA is converted from glutamate by the enzyme glutamic acid decarboxylase (GAD). GAD is the rate-limiting step of the synthesis of GABA.

Despite their pervasiveness in brain activity and function, these amino acid neurotransmitters have received very little attention in the study of autism. However, researchers have begun to investigate whether or not either substance could play a role in autism’s expression. This is, in some respects, a different approach from previous neurochemical investigations. Rather than trying to identify multiple abnormalities in relatively independent systems, the study of glutamate and GABA posits that autism may be the result of a single dysfunction that in turn has broad repercussions (Hussman, 2001).

Most theories regarding these amino acid neurotransmitters in autism suggest that the GABAergic system is suppressed, resulting in excessive stimulation of the glutamate system. This can be attributed to several findings. First, researchers have found abnormalities of cellular development in the limbic system and cerebellum postmortem (Bauman & Kemper, 1994; Raymond, Bauman, & Kemper, 1996). These areas are normally enriched with glutamate receptors. Researchers have theorized that overactivity of glutamate could result in “excitotoxicity” which could cause aberrant neuronal development (Bittigau & Ikonomidou, 1997). In addition, glutamate activity peaks during the second year of life (Kornhuber, Mack-Burhardt, Konradi, Fritze, & Riderer, 1989), which is a time when symptoms of autism often emerge. If this system is hyperfunctional, it is possible that neuronal growth and connectivity are damaged during critical periods of development. Excessive glutamatergic stimulation is also associated with seizures, which are common among individuals with autism (Hussman, 2001).

Recently, a group of researchers examined brain levels of GAD, the rate-limiting step in the synthesis of GABA, in five autistic and eight control subjects postmortem (Fatemi et al., 2002). They found that this enzyme was reduced by 48–61% in parietal and cerebellar areas of brains of individuals with autism when compared to controls. These differences were statistically significant, and provided some initial evidence for abnormalities in glutamate/GABA.

At this point, it is unclear as to whether or not an imbalance in the glutamate and GABA neurotransmitters contributes to the etiology of autism. However, postmortem research in this area is intriguing, and further research is needed.

9.1. Clinical/treatment implications

Much is already known about both glutamate and GABA metabolism and neurotransmission in general that might be applied empirically case-by-case in autism. The classic GABAergic agents available, such as clonazepam and lorazepam, seem of relatively low risk other than addiction or sudden withdrawal. Another intriguing possibility, one that would require long-term research to establish benefit-risk ratio, would be preventative treatment with GABA agents when autism first manifests in toddlerhood to neutralize excess glutamate excitotoxicity and to prevent progression of the disorder. However, the existing trials are not cause for optimism. Two studies examining pharmacologic treatments that affect the glutaminergic system were located. One assessed the effects of lamotrigine, which is thought to modulate glutamate’s activity but which also weakly inhibits the serotonin 5HT3 receptor (Belsito, Law, Kirk, Landa, & Zimmerman, 2001). In a double-blind, placebo-controlled study, either lamotrigine or placebo was
administered to twenty-eight children with autism, aged between 3 and 11 years, chosen for the presence of autism but no additional behavioral symptoms. Very little improvement in autism symptoms was noted with treatment with active drug. King et al. (2001) reported findings from a double-blind, placebo-controlled study of amantadine (an antagonist at the \(N\)-methyl-D-aspartate subtype of glutamate receptor but also with anticholinergic effects) in 39 subjects with autistic disorder. While significant improvements were noted on the clinician-rated scores for Hyperactivity and Inappropriate Speech subscales of the Aberrant Behavior Checklist (Aman, Singh, Stewart, & Field, 1985) during treatment with amantadine, no differences from placebo were noted for parent measures (Aberrant Behavior Checklist) and in clinician’s ratings of global improvement.

Hollander, Dolgoff-Kasper, Cartwright, Rawitt, and Novotny (2001) openly treated 14 patients (mostly children) with autism spectrum disorders with divalproex sodium (DVPX). DVPX inhibits catabolic enzymes of GABA, but it also blocks voltage-dependent sodium channels. The patients were described as having affective instability (e.g., were impulsive and aggressive). Retrospective analysis suggested that 10 patients (72%) showed improved behavior with DVPX. Marrosu, Marrosu, Rachel, and Biggio (1987) described a series of seven children with autism who received intramuscular injections of diazepam and saline. Six of the seven children showed hyperactivity and all exhibited aggression when medicated with diazepam. Such an adverse response should not be surprising. It has long been known that children often show ‘paradoxical’ excitability when treated with anxiolytic/sedatives (Werry & Aman, 1999) and children with autism appear to be no exception.

10. Discussion

At first glance, the bulk of neurochemical research in autism has been inconclusive, contradictory, and somewhat disappointing. Most of these studies employed few subjects and included comparison groups that were not appropriate, making it difficult to draw clear-cut conclusions. However, there appear to be some areas that may prove fruitful for future researchers. Clearly, serotonin remains the most promising area for future neurochemical research. With the development of sophisticated imaging and genetic techniques, researchers are beginning to delineate the potential abnormalities in central serotonergic functioning, such as focal regions of abnormal 5-HT synthesis and possible genetic differences in 5-HT transport. These preliminary results are intriguing and are in need of further study and replication.

Recent work in neuropeptide functioning has suggested that oxytocin may also play a role in the pathogenesis of the disorder. This area of research is in its infancy, and further study is needed; particularly, it would be useful to get more direct central assessments of oxytocin via measurement of CSF. In addition, studies using positron-emission tomography to investigate central OT receptor distribution may also help elucidate the role of oxytocin in autism (Modahl et al., 1998).

The place of neurotransmitters in early brain development (e.g., serotonin, acetylcholine, and glutamate) may prove to be a particularly important area of study. If certain systems are disrupted early in the development of the brain, it is possible that early pharmacological intervention could possibly help to treat and maybe even prevent some of the devastating features of autistic disorder. Theoretically, work in genetics may be able to identify these neurochemical abnormalities at birth, which may help to direct infants who are at risk for autism into the appropriate medical treatment. This would represent a completely new approach to the pharmacological management of autism.

Review of the other neurochemical systems in autism was not as compelling. The evidence
for DA’s role in autism was not convincing; however, there are discrepancies among the studies of central DA turnover, so further replication may be warranted. The studies of noradrenergic functioning have not provided any evidence for a clear role in autism’s pathogenesis, and it is unlikely that further investigation would prove otherwise. Studies of opioid functioning in autism have not produced much of clinical relevance thus far. Studies of baseline levels of cortisol have not shown any consistent abnormalities, though a high rate of non-suppression after dexamethasone warrants further pursuit.

Upon review of this body of work, several methodological issues need to be addressed by future researchers. First, it is critical that future studies carefully assess and categorize research subjects by strict diagnostic and subject criteria for autism. Perusal of Tables 1–6 reveals that everything from “clinical impression” through to rigorous structured interview has been used in the past, but entry has relied on informal methods of classification in the past. Future research needs to go beyond the sole reliance on diagnostic methods such as the DSM-IV and the ADI-R in classifying subjects. Though these tools may be able to diagnose an individual with autistic disorder, there are inconsistent symptom profiles across individuals who meet these criteria. For example, individuals may be severely or mildly impaired, and may exhibit comorbid behavioral disturbances such as hyperactivity, aggression, or anxiety – such subject factors may likely reflect neurochemical function. Furthermore, recent research has also established that factors such as pubertal status and race can have significant effects on biochemical measurements. These characteristics must also be accounted for in control groups. Researchers need to control for these subject variables, and in doing so, they will be able to delineate what is unique to the pathophysiology of autism, and possibly reveal subcategories within the disorder that may guide future pharmacotherapy.

Second, much of the neurochemical research in the past 35 years or so has focused on peripheral measures of neurochemical systems; this has limited what conclusions could be made about central functioning. However, recent advances in the basic neurosciences (such as PET, genetic techniques, and more sensitive assay methods) have opened the way to more relevant and informative assessments of central functioning. Thus, in time, the greatest challenge to meaningful neurochemical investigation in autism may well be the issues of clinical assessment discussed above (rather than limitations in neurobiological assessment).

Third, looking for abnormalities in only one neurochemical system may be akin to searching for the “Holy Grail”. For example, it is not clear why the atypical antipsychotics are often helpful in managing problem behaviors in autism. In this case, it could be that there is a dynamic balance between serotonergic and dopaminergic systems, and that this varies between patients, as well as between drugs. For example, serotonin is also known to have a regulatory action on dopamine levels. This idea of dynamic interaction might also be applied to other neurotransmitters, neuropeptides, and so forth. Thus, it may be more fruitful to look for a pattern of imbalance between candidate neurotransmitters than for simple elevations and deficiencies.

Fourth, it is clear that the various subspecialties within the biological bases of behavior must continue (and increase) their collaborative efforts. The disciplines of neurochemistry, neuroanatomy, psychopharmacology, and genetics should work in concert to help uncover the biological bases of this disorder. It is becoming clear that autism may involve a cascade of complex gene-environmental interactions, and the study of neurochemistry in isolation may not be sufficient. This includes approaching the study of autism from a developmental perspective, investigating how early neuronal growth and differentiation could be aberrant or interrupted in individuals with the disorder. Recent advances in pharmacogenomics may prove to be a fruitful area of research, as may
the continued postmortem studies of receptor distribution and neurochemistry. Bringing together experts of these respective areas to work in collaboration with one another is an exciting development that will hopefully lead to better treatments, if not a cure or prevention for this debilitating disorder.

References


Insel, T. R., & Hulihan, T. J. (1995). A gender specific mechanism for pair bonding: oxytocin and partner preference...


Research Units on Pediatric Psychopharmacology Autism Network. (2002). Risperidone in children with autism and


